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anglais
A beneficial effect of recombinant activated factor VII (rFVIIa) in Child-Pugh class B
and C patients with cirrhosis who have variceal bleeding has been suggested. This
randomized controlled trial assessed the efficacy and safety of rFVIIa in patients with
advanced cirrhosis and active variceal bleeding. At 31 hospitals in an emergency
setting, 256 patients (Child-Pugh > 8; Child-Pugh B = 26%, C = 74%) were
randomized equally to: placebo; 600 μg/kg rFVIIa (200 + 4× 100 μg/kg); or 300
μg/kg rFVIIa (200 + 100 μg/kg). Dosing was intravenous at 0, 2, 8, 14, and 20 hours
after endoscopy, in addition to standard vasoactive, prophylactic antibiotic, and
endoscopic treatment. The primary composite endpoint consisted of failure to control
24-hour bleeding, or failure to prevent rebleeding or death at day 5. Secondary
endpoints included adverse events and 42-day mortality. Baseline characteristics
were comparable between groups. Administration of rFVIIa had no significant effect
on the composite endpoint compared with placebo (P = 0.37). There was no
significant difference in 5-day mortality between groups; however, 42-day mortality
was significantly lower with 600 μg/kg rFVIIa compared with placebo (odds ratio
0.31, 95% confidence interval = 0.13–0.74), and bleeding-related deaths were
reduced from 12% (placebo) to 2% (600 μg/kg). A marked heterogeneity in the
failure rate in all treatment groups was observed across participating centers.
Adverse events, including overall thromboembolic events, were comparable between
groups. Conclusion: Treatment with rFVIIa had no significant effect on the primary
composite endpoint compared with placebo. Therefore, decision on the use of this
hemostatic agent in acute variceal bleeding should be carefully considered, because
results of this study do not support the routine use of rFVIIa in this setting. Adverse
events were comparable across groups.
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